Treatment efficacy of high dose progestin in young women with early stage of endometrial carcinoma.
- Author:
Yun Hyun CHO
1
;
Dae Shik SUH
;
Yong Il JI
;
Dae Yeon KIM
;
Jong Hyeok KIM
;
Yong Man KIM
;
Young Tak KIM
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea. dssuh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
High dose progestin therapy;
Early endometrial carcinoma
- MeSH:
Adenocarcinoma;
Curettage;
Endometrial Neoplasms*;
Female;
Fertility;
Humans;
Hysterectomy;
Medroxyprogesterone Acetate;
Megestrol Acetate;
Progestins;
Treatment Outcome*
- From:Korean Journal of Obstetrics and Gynecology
2007;50(3):486-493
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study is to investigate the effectiveness of high dose progestins in young patients with early stage of endometrial cancer. METHODS: Between April 1998 and December 2005, 10 women with early stage of endometrial carcinoma were treated with high dose progestins as primary therapy for the purpose of saving fertility. RESULTS: They took 80~160 mg of megestrol acetate or 500~1,000 mg of medroxyprogesterone acetate per day, and then followed up with the endometrial curettages. Seven patients (70.0%) responded to the treatment. Three patients didn't respond and so underwent hysterectomy as definite treatment. Four patients were able to become pregnant after completing treatment. No patients died of their disease. CONCLUSION: The majority of patients with well-differentiated endometrial adenocarcinoma who underwent conservative treatment with a progestational agent responded to the treatment. High-dose progestin therapy can be used as primary therapy in selected young women with early stage of endometrial carcinoma.
